Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions,
Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for argenx in a research report issued to clients ...
Upstart investment bank SVB Leerink is no longer keeping mum on its ambitions to push into the red hot technology, media, and telecommunications market. The dealmaking unit of SVB Financial Group ...
today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners ...
Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of DENTSPLY SIRONA in a ...
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Outperform recommendation. As of January 29, 2025, the average one-year price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback